A phase II, randomized, parallel group, placebo-controlled, double-blinded, dose-finding study to evaluate efficacy, safety, tolerability, and pharmacokinetics of ABY-035 in subjects with moderate-to-severe plaque psoriasis
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2018
At a glance
- Drugs ABY 035 (Primary)
- Indications Psoriasis
- Focus Proof of concept; Therapeutic Use
- Acronyms AFFIRM-35
- Sponsors Affibody
- 21 Mar 2018 According to a Affibody media release, the first patient has been dosed in this study.
- 17 Nov 2017 According to a Affibody Medical AB media release, the German regulatory agency BfArM approved the clinical trial application (CTA) for the Phase II study with ABY-035 in Nov 2017.
- 24 May 2017 New trial record